BAFNA PHARMACEUTICALS
|
BAFNA PHARMACEUTICALS Last 5 Year Financial Ratios History
[Standalone]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 1.76 | 3.11 | 4.79 | 2.21 | 2.46 |
| CEPS(Rs) | 3.82 | 5.22 | 7.05 | 4.53 | 4.36 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 35.85 | 34.17 | 31.05 | 26.19 | 24.00 |
| Tax Rate(%) | - | - | 2.40 | - | - |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 7.46 | 7.29 | 13.62 | 13.98 | 14.46 |
| EBIT Margin(%) | 4.72 | 6.32 | 11.84 | 7.06 | 9.22 |
| Pre Tax Margin(%) | 2.85 | 4.82 | 10.07 | 6.13 | 8.18 |
| PAT Margin (%) | 2.85 | 4.82 | 9.83 | 6.13 | 8.18 |
| Cash Profit Margin (%) | 6.20 | 8.10 | 14.45 | 12.58 | 14.47 |
| Performance Ratios | |||||
| ROA(%) | 2.76 | 5.30 | 10.32 | 5.91 | 7.40 |
| ROE(%) | 5.01 | 9.52 | 16.75 | 8.79 | 22.26 |
| ROCE(%) | 6.31 | 9.56 | 16.12 | 8.42 | 10.62 |
| Asset Turnover(x) | 0.97 | 1.10 | 1.05 | 0.96 | 0.90 |
| Sales/Fixed Asset(x) | 1.42 | 1.57 | 1.26 | 1.02 | 0.93 |
| Working Capital/Sales(x) | 4.44 | 3.84 | 2.82 | 2.95 | 2.81 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.70 | 0.64 | 0.79 | 0.98 | 1.08 |
| Receivable days | 107.07 | 103.59 | 88.49 | 52.17 | 39.96 |
| Inventory Days | 72.23 | 62.08 | 67.24 | 76.57 | 68.82 |
| Payable days | 149.66 | 134.43 | 118.26 | 105.56 | 133.55 |
| Valuation Parameters | |||||
| PER(x) | 42.73 | 24.68 | 17.24 | 57.59 | 55.74 |
| PCE(x) | 19.62 | 14.69 | 11.73 | 28.05 | 31.52 |
| Price/Book(x) | 2.09 | 2.24 | 2.66 | 4.85 | 5.72 |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 1.39 | 1.34 | 1.83 | 3.66 | 4.72 |
| EV/Core EBITDA(x) | 14.53 | 13.96 | 11.09 | 22.79 | 30.42 |
| EV/EBIT(x) | 29.37 | 21.20 | 15.43 | 51.80 | 51.15 |
| EV/CE(x) | 1.79 | 1.94 | 2.19 | 3.45 | 3.89 |
| M Cap / Sales | 1.22 | 1.19 | 1.70 | 3.53 | 4.56 |
| Growth Ratio | |||||
| Net Sales Growth(%) | -4.33 | 32.18 | 35.48 | 19.55 | 67.68 |
| Core EBITDA Growth(%) | -4.88 | -22.93 | 39.00 | 23.66 | 644.34 |
| EBIT Growth(%) | -28.58 | -29.41 | 127.17 | -8.50 | 468.50 |
| PAT Growth(%) | -43.49 | -35.19 | 117.34 | -10.47 | 410.26 |
| EPS Growth(%) | -43.49 | -35.19 | 117.34 | -10.47 | 131.03 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.33 | 0.30 | 0.31 | 0.18 | 0.23 |
| Current Ratio(x) | 1.63 | 1.73 | 1.88 | 2.31 | 2.04 |
| Quick Ratio(x) | 1.09 | 1.19 | 1.40 | 1.39 | 1.41 |
| Interest Cover(x) | 2.52 | 4.21 | 6.70 | 7.57 | 8.85 |
| Total Debt/Mcap(x) | 0.16 | 0.13 | 0.12 | 0.04 | 0.04 |
Compare Financial Ratios of peers of BAFNA PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| BAFNA PHARMACEUTICALS | ₹390.9 Cr | 11.5% | -3.5% | 91.4% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹421,131.0 Cr | -0.7% | -0.5% | -3.1% | Stock Analytics | |
| DIVIS LABORATORIES | ₹171,862.0 Cr | 2.9% | 1.8% | 11.9% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹129,254.0 Cr | 1.5% | 3.4% | 12.4% | Stock Analytics | |
| CIPLA | ₹121,198.0 Cr | 0.2% | -0.2% | 0.4% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹107,083.0 Cr | 0.9% | 4.8% | -3.2% | Stock Analytics | |
BAFNA PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| BAFNA PHARMACEUTICALS | 11.5% |
-3.5% |
91.4% |
| SENSEX | 1% |
0.3% |
6.7% |
You may also like the below Video Courses
